Wegovy (Semaglutide) Drug Shortage Guide for Healthcare Providers

The Wegovy shortage has created real clinical challenges for prescribers across the country — disrupted treatment plans, frustrated patients, and complex decisions about alternative therapies. This guide gives you a practical framework for navigating the shortage landscape, evaluating therapeutic alternatives, managing prior authorizations, and communicating effectively with patients. You'll also find guidance on how to use FindUrMeds as a resource when your patients can't locate their medication.

---

The Current Wegovy Shortage: What Prescribers Need to Know

Wegovy (semaglutide 2.4 mg subcutaneous injection) has faced intermittent supply shortages since its initial FDA approval in June 2021, with demand consistently outpacing manufacturing capacity. At its peak, multiple dose strengths were simultaneously listed on the FDA's drug shortage database, leaving patients stranded mid-titration — often at the worst possible time therapeutically.

The shortage picture today is fluid. Novo Nordisk has made significant investments in manufacturing scale-up, and availability has improved compared to the 2022–2023 peak shortage period. However, regional disparities remain common. A patient in one zip code may fill their prescription without difficulty while another patient twenty miles away encounters weeks of backorders. Lower titration doses (0.25 mg and 0.5 mg) have historically been the most constrained, which creates a specific problem: new patients can't start therapy even when maintenance doses are in stock.

The practical reality for your practice: You cannot assume a written prescription translates to a dispensed medication. Building a shortage-awareness protocol into your prescribing workflow — rather than managing it reactively — will save your patients and your staff significant time and frustration.

---

Therapeutic Alternatives and Switching Protocols

When Wegovy is unavailable, you have several evidence-based options. The right choice depends on your patient's indication, comorbidities, insurance situation, and how far along they are in their treatment.

Option 1: Ozempic (Semaglutide 1 mg or 2 mg — Same Molecule, Different Indication)

This is the most pharmacologically straightforward option. Ozempic contains the same active ingredient as Wegovy but is FDA-approved for type 2 diabetes, not chronic weight management. A few important considerations:

• Insurance coverage: Most commercial plans and Medicare will not cover Ozempic for obesity without a diabetes diagnosis. Prior authorization requirements differ significantly. Document clearly if prescribing off-label.
• Maximum dose: Ozempic is approved up to 2 mg weekly; Wegovy reaches 2.4 mg. For patients who have reached or are approaching maintenance dosing on Wegovy, this difference may be clinically meaningful.
• Prescribing note: Do not simultaneously prescribe both products. The FDA has flagged this as a medication safety concern.

Option 2: Zepbound (Tirzepatide)

Tirzepatide (GIP/GLP-1 dual agonist) received FDA approval for chronic weight management in November 2023. Clinical trial data from the SURMOUNT program showed mean weight loss of approximately 20–22% at 72 weeks with the 15 mg dose — outcomes that compare favorably to semaglutide in indirect comparisons, and which were confirmed in the head-to-head SURMOUNT-5 trial.

Switching protocol considerations:

• No mandatory washout period is required when switching between GLP-1 or dual GIP/GLP-1 agonists, but restart titration from the lowest dose to minimize GI side effects.
• Inform patients that onset of effect may feel different — tirzepatide's dual mechanism can produce a distinct tolerability profile.
• Check formulary coverage before switching. Zepbound is covered differently than Wegovy across commercial plans.

Option 3: Saxenda (Liraglutide 3 mg)

Liraglutide is a daily injectable GLP-1 agonist approved for weight management. It's an older agent with a well-established safety profile, though weight loss efficacy is more modest — approximately 5–8% mean body weight reduction versus 15%+ with semaglutide.

• Best suited for patients who cannot tolerate weekly injectables or who have specific contraindications to semaglutide/tirzepatide.
• Injection burden (daily vs. weekly) is a meaningful consideration for patient adherence.
• Prior authorization requirements vary; some payers prefer liraglutide as a step-therapy requirement before approving Wegovy anyway.

Option 4: Oral Semaglutide (Rybelsus)

Rybelsus (semaglutide 7 mg or 14 mg oral) is approved for type 2 diabetes, not weight management. Bioavailability is significantly lower than subcutaneous semaglutide, and weight loss data in the obesity population is limited compared to Wegovy. This is generally not a like-for-like substitute, but may bridge certain patients while injectable supply is restored.

---

Prior Authorization Considerations During Shortages

Switching medications due to a shortage adds a layer of prior authorization complexity that your team should anticipate.

Document the shortage explicitly. When submitting PA requests for alternative agents, include documentation that Wegovy is unavailable — not simply that the patient prefers a different medication. Many payers have shortage-specific language in their appeals processes.

Request a formulary exception or medical necessity override. If your patient has documented weight-related comorbidities (hypertension, sleep apnea, cardiovascular disease, pre-diabetes), emphasize these in the PA narrative. Payers are more likely to approve alternatives — and at lower cost-sharing tiers — when medical necessity is clearly established.

Continuity of care arguments matter. For patients who have achieved clinically significant weight loss on Wegovy, disrupting therapy carries real risk: weight regain is well-documented when GLP-1 therapy is discontinued. This is a compelling argument for expedited PA approval of a therapeutic alternative.

Check shortage-related PA waivers. During declared shortage periods, some insurers temporarily waive step-therapy requirements or PA processes. Have your prior authorization staff check payer bulletins regularly — these policies can change quickly and aren't always proactively communicated.

---

Clinical Considerations When Switching

A few clinical pearls to keep in mind when transitioning patients between agents:

• Restart titration. Even if a patient was well-established on Wegovy 2.4 mg, switching to a new agent warrants restarting from the lowest available dose. GI adverse effects (nausea, vomiting, gastroparesis symptoms) are the most common reason patients discontinue therapy — a conservative uptitration protects adherence.
• Monitor weight and metabolic parameters at 8–12 weeks post-switch. Set realistic expectations: some patients will have equivalent or better outcomes on alternative agents; others may lose ground temporarily.
• Reassess cardiovascular risk context. For patients with established cardiovascular disease, note that Wegovy specifically carries an FDA-approved cardiovascular risk reduction indication (SELECT trial data). If CV risk reduction is a primary clinical goal alongside weight management, document this in your transition rationale.
• Watch for polypharmacy interactions. Slowed gastric emptying can affect absorption of oral medications — this is a class effect of GLP-1 agonists, but degree varies by agent and dose. Review your patient's oral medication list during any agent switch.

---

Communicating With Patients About the Shortage

How you frame the shortage matters enormously for patient trust and treatment adherence. A few approaches that work well in practice:

Lead with validation, not logistics. Patients who have worked hard to reach a stable dose on Wegovy — and who may have already lost meaningful weight — can feel genuinely blindsided by a supply disruption. Acknowledge that before getting into alternatives.

Be specific about what you know and don't know. "We don't have a confirmed timeline for when Wegovy will be reliably back in stock in your area" is more useful than vague reassurance. Patients can handle uncertainty when it's framed honestly.

Explain the therapeutic rationale for any switch. Patients who understand why tirzepatide or liraglutide is a reasonable bridge — not just a second-best option — are more likely to start the new medication promptly and adhere to the titration schedule.

Set expectations about efficacy timelines. If switching agents, remind patients that full efficacy at a new maintenance dose takes time. Weight may plateau or temporarily trend upward during the transition — this is not treatment failure.

Direct patients to practical resources. For detailed patient-facing guidance on locating in-stock Wegovy at nearby pharmacies, see how to help patients find Wegovy in stock. For cost-saving strategies if they need to pay out of pocket during the shortage, see how to help patients save money on Wegovy.

---

How to Use FindUrMeds as a Provider Resource

FindUrMeds was built for exactly this kind of situation. When your patient has a valid prescription but can't locate Wegovy in stock, FindUrMeds contacts pharmacies on their behalf — searching across 15,000+ locations nationwide, including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — and typically identifies an in-stock location within 24–48 hours.

How this integrates into your workflow:

You don't need to change how you prescribe. If a patient calls your office unable to fill their Wegovy prescription, direct them to findurmeds.com. FindUrMeds handles the pharmacy legwork, so your staff isn't spending time calling pharmacies and your patient isn't going without medication longer than necessary.

FindUrMeds is already trusted by 200+ healthcare providers and reports a 92% success rate locating prescriptions that patients couldn't find on their own.

A practical note for your front desk or care coordination team: Including FindUrMeds in your shortage response protocol — alongside any payer communication templates or PA support processes — gives patients a concrete first step rather than leaving them to navigate the shortage independently.

---

Quick Reference: Shortage Response Checklist for Providers

• Confirm Wegovy availability in your patient's zip code before the shortage becomes a crisis
• Identify preferred therapeutic alternative based on patient comorbidities and payer formulary
• Restart titration when switching to any new agent
• Document shortage explicitly in PA submissions for alternative agents
• Brief patient on transition rationale and realistic efficacy timeline
• Direct patients to FindUrMeds if they're unable to locate in-stock medication
• Monitor weight and tolerability at 8–12 weeks post-switch
• Revisit Wegovy re-initiation when supply stabilizes and insurance coverage allows

---

FAQ for Healthcare Providers

Can I prescribe Ozempic in place of Wegovy for a patient without type 2 diabetes?

Yes, you can prescribe Ozempic off-label for weight management, but it's important to be transparent with patients and payers. Most insurance plans will not cover Ozempic for obesity without a diabetes diagnosis, which could leave patients with significant out-of-pocket costs. Always document your clinical rationale, and check your state's prescribing regulations around off-label use if there is any question.

Is there a mandatory washout period when switching from Wegovy to tirzepatide?

No mandatory washout period is required. However, clinical best practice is to restart the new agent at its lowest titration dose regardless of what dose the patient was on with semaglutide. This minimizes GI adverse events and sets the patient up for better long-term tolerability on the new medication.

How do I handle a patient who is mid-titration when the shortage hits?

This is the most clinically sensitive scenario. If a patient is below the 1 mg dose, prioritize finding in-stock semaglutide at that dose — even if it means geographic flexibility — before moving to an alternative agent. If supply is genuinely unavailable, initiate the alternative agent at the lowest available dose and counsel the patient carefully on the transition. Avoid simply stopping therapy without a plan: discontinuation is associated with meaningful weight regain.

Will insurance cover a therapeutic alternative during a documented shortage?

It depends on the payer and the specific alternative. During active shortage periods, some insurers issue temporary coverage exceptions or waive step-therapy requirements — but these are not universal. The strongest PA submissions document both the shortage and the patient's medical necessity for continued therapy. Appeals citing continuity of care and documented clinical benefit have a reasonable success rate, particularly when supported by comorbidity data.

---

Need help finding Wegovy in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Wegovy Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →